Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03658343 · ClinicalTrials.gov registry record
T2* MRI Analysis for Sarcoma
A clinical trial of Sarcoma and Magnetic Resonance Imaging, sponsored by Bryan Allen.
- Completed
- Registry status
- 8
- Enrollment target
- 1
- Study location
NCT03658343 is a study of Sarcoma and Magnetic Resonance Imaging that has completed, run by Bryan Allen. The registered enrollment target is 8 participants, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03658343, a study of Sarcoma and Magnetic Resonance Imaging, has completed, sponsored by Bryan Allen.
- COMPLETED
- Registry status
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
T2\* imaging is a method to identify labile iron pools in tumor cells. These iron pools may be linked to better treatment outcomes for specific types of therapy. This is a small pilot study to see if radiation therapy changes the amount of iron in a sarcoma tumor.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST T2* Imaging
Study Locations (1)
Iowa
- Holden Comprehensive Cancer Center - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2018-09-18 |
| Est. Completion | 2022-02-25 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03658343
The ClinicalTrials.gov registry entry for NCT03658343 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (99% lower). The listed sponsor is Bryan Allen, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Sarcoma appearing as the primary indexed condition, and to 1 intervention - of which T2* Imaging is the first listed.
NCT03658343 reports 1 study location spanning 1 distinct geographic area - top geographies include Iowa.
Frequently Asked Questions
What is clinical trial NCT03658343 about?
NCT03658343 is a clinical study titled "T2* MRI Analysis for Sarcoma". T2\* imaging is a method to identify labile iron pools in tumor cells. These iron pools may be linked to better treatment outcomes for specific types of therapy. This is a small pilot study to see if radiation therapy changes the amount of iron in a sarcoma tumor.
What is the current status of trial NCT03658343?
This trial is currently completed. The enrollment target is 8 participants. The study started on 2018-09-18. Estimated completion is 2022-02-25.
What conditions does trial NCT03658343 study?
This clinical trial studies the following conditions: Sarcoma, Magnetic Resonance Imaging, Radiotherapy.
What interventions are being tested in trial NCT03658343?
The interventions under investigation include: T2* Imaging (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03658343?
This trial is sponsored by Bryan Allen, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03658343 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
WATCH (Wearable Artificial inTelligence for Cardiac Function and Health Monitoring)
RECRUITING · NA
-
LCI-SAR-BSTS-CTDNA-001: Circulating Tumor DNA Liquid Biopsy in Sarcoma Patients
RECRUITING
-
Palbociclib and Pembrolizumab in Sarcoma
RECRUITING · Phase 1
-
Abductor Reattachment Methods in Proximal Femur Replacements: What is the Best Method?
RECRUITING
-
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
RECRUITING · Phase 1
-
Enhanced Recovery After Surgery in Extremity Sarcoma
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.